Atrium Therapeutics, Inc. (RNA) Balance Sheet
RNA balance sheet, 2025
December 31, 2025 · U.S. dollars$278.4M assets = $71.1M liabilities + $207.3M equity
Both columns are drawn to the same scale: what RNA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
RNA financial health
Descriptive bands, not a rating. Fiscal 2025.
RNA balance sheet trends, 2012–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $62.4M2012 | $278.4M2025 | +18.1%/yr | |
| Total liabilities | $41.9M2012 | $71.1M2025 | +6.1%/yr | |
| Shareholders’ equity | $20.5M2012 | $207.3M2025 | +29.3%/yr | |
| Cash & short-term investments | $53.7M2012 | $270.0M2025 | +19.7%/yr | |
| Total debt | $8.2M2012 | $3.7M2025 | −8.5%/yr | |
| Net cash (debt) | $45.5M2012 | $266.3M2025 | +$220.8M | |
| Working capital | −$1.4M2018 | $231.0M2025 | +$232.4M | |
| Book value per share | −$1.992018 | $12.112025 | — | |
| Current ratio | 0.702018 | 6.532025 | +5.82 | |
| Debt / equity | 0.402012 | 0.022025 | −0.38 | |
| Shares outstanding | 20.7M2018 | 17.1M2025 | −2.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RNA assets
RNA liabilities and equity
RNA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
RNA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $270.0M | $1.50B | $595.4M | $610.7M | $405.5M | $328.1M | $94.6M | $3.1M | $113.3M | $53.7M |
| Cash & equivalents | $270.0M | $219.9M | $185.1M | $340.4M | $320.4M | $328.1M | $94.6M | $3.1M | $113.3M | $53.7M |
| Short-term investments | $1.31B | $1.28B | $410.3M | $270.3M | $85.1M | $6.7M | — | — | — | — |
| Receivables | $12.4M | $28.2M | $8.6M | $3.9M | $900,000 | $1.2M | $800,000 | $0 | $0 | $0 |
| Inventory | $0 | $0 | −$7.3M | $1 | −$900,000 | −$1.2M | $1 | $0 | $0 | $0 |
| Other current assets | $0 | $12.6M | $14.7M | $8.3M | $5.6M | $3.5M | $297,999 | $152,000 | — | — |
| Total current assets | $272.8M | $1.54B | $611.3M | $622.9M | $411.1M | $331.7M | $95.7M | $3.2M | — | — |
| Property, plant & equipment (net) | $5.5M | $18.3M | $16.7M | $15.0M | $15.6M | $1.5M | $631,000 | $702,000 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.0M | $1.1M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $3.3M | $596,000 | $849,000 | $850,000 | $752,000 | $600,000 | $38,000 | $124.1M | $61.3M |
| Total assets | $278.4M | $1.56B | $628.6M | $638.8M | $427.6M | $333.9M | $96.9M | $4.0M | $125.1M | $62.4M |
| Liabilities | ||||||||||
| Accounts payable | $4.4M | $8.5M | $8.8M | $4.6M | $2.8M | $7.7M | $2.3M | $1.6M | $2.6M | $3.2M |
| Short-term debt | $3.7M | $3.8M | $3.6M | $3.1M | $1.8M | $7.7M | $2.8M | $2.7M | — | — |
| Deferred revenue | $21.6M | $21.0M | $28.4M | $5.0M | $4.9M | $3.7M | $3.8M | — | — | — |
| Total current liabilities | $41.8M | $98.0M | $80.7M | $51.9M | $29.7M | $14.6M | $10.2M | $4.6M | $12.5M | $16.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $1.8M | $7.6M | $10.5M | $8.2M |
| Lease obligations | $3.7M | $6.8M | $9.9M | $7.6M | $11.7M | $938,000 | $393,000 | $0 | — | — |
| Other long-term liabilities | $29.3M | $40.9M | $47.1M | $8.8M | $16.5M | $13.1M | $150.3M | $32.9M | $15.0M | $17.6M |
| Total liabilities | $71.1M | $138.9M | $127.8M | $60.7M | $46.1M | $27.7M | $162.3M | $45.1M | $38.0M | $41.9M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $17,000 | $12,000 | $8,000 | $7,000 | $5,000 | $4,000 | $1,000 | $426,000 | $495,000 | $382,000 |
| Retained earnings (deficit) | −$1.58B | −$893.1M | −$570.8M | −$358.5M | −$184.5M | −$66.5M | −$22.2M | −$41.6M | — | — |
| Accumulated other comprehensive income | $2.6M | $2.9M | $125,000 | −$2.7M | −$186,999 | −$5,000 | −$134.7M | −$33.1M | — | — |
| Total shareholders' equity | $207.3M | $1.42B | $500.8M | $578.1M | $381.4M | $306.2M | −$65.4M | −$41.1M | $87.1M | $20.5M |
| Key figures | ||||||||||
| Total debt | $3.7M | $6.8M | $9.9M | $10.7M | $11.7M | $938,000 | $4.9M | $10.3M | $10.5M | $8.2M |
| Net cash (debt) | $266.3M | $1.49B | $585.5M | $600.0M | $393.8M | $327.2M | $89.6M | −$7.2M | $102.8M | $45.5M |
| Working capital | $231.0M | $1.44B | $530.6M | $571.0M | $381.5M | $317.1M | $85.4M | −$1.4M | — | — |
| Tangible book value | $207.3M | $1.42B | $500.8M | $578.1M | $381.4M | $306.2M | −$65.4M | −$41.1M | $86.1M | $19.4M |
| Book value per share | $12.11 | — | $6.86 | $11.08 | $9.21 | $14.14 | −$1.74 | −$1.99 | — | — |
| Shares outstanding | 17.1M | — | 73.0M | 52.2M | 41.4M | 21.7M | 37.5M | 20.7M | — | — |
| Current ratio | 6.53 | 15.73 | 7.58 | 12.00 | 13.86 | 22.74 | 9.35 | 0.70 | — | — |
| Quick ratio | 6.76 | 15.61 | 7.49 | 11.84 | 13.70 | 22.58 | 9.32 | 0.67 | 9.06 | 3.34 |
| Debt / equity | 0.02 | 0.00 | 0.02 | 0.02 | 0.03 | 0.00 | — | — | 0.12 | 0.40 |
| Equity / assets | 74.5% | 91.1% | 79.7% | 90.5% | 89.2% | 91.7% | −67.4% | −1,032.9% | 69.6% | 32.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $264.2M | $267.8M | $270.0M | $270.0M | $1.18B | $1.38B | $1.50B | $1.59B | $1.30B | $915.9M | $595.4M | $542.6M |
| Cash & equivalents | $72.6M | $267.8M | $270.0M | $270.0M | $243.9M | $254.2M | $219.9M | $370.2M | $575.8M | $471.4M | $185.1M | $85.7M |
| Short-term investments | $191.6M | — | $1.31B | $1.53B | $939.2M | $1.13B | $1.28B | $1.22B | $723.3M | $444.5M | $410.3M | $456.9M |
| Receivables | $0 | $15.0M | $12.4M | $15.0M | $8.5M | $36.6M | $28.2M | $19.2M | $15.7M | $9.0M | $8.6M | $1.0M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$15.7M | $0 | $0 | −$1.0M |
| Other current assets | $10.8M | $2.7M | $0 | $0 | $58.9M | $18.5M | $12.6M | $14.1M | $29.8M | $9.6M | $7.3M | $12.9M |
| Total current assets | $275.1M | $285.6M | $272.8M | $271.3M | $1.25B | $1.43B | $1.54B | $1.62B | $1.33B | $934.5M | $611.3M | $555.5M |
| Property, plant & equipment (net) | $5.4M | $6.4M | $5.5M | $6.3M | $24.8M | $20.6M | $18.3M | $15.8M | $15.5M | $16.3M | $16.7M | $17.0M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $106,000 | $415,000 | $0 | $0 | $93.6M | $3.5M | $3.3M | $3.1M | $3.2M | $720,000 | $596,000 | $639,000 |
| Total assets | $280.5M | $292.4M | $278.4M | $277.5M | $1.37B | $1.46B | $1.56B | $1.64B | $1.35B | $951.5M | $628.6M | $573.2M |
| Liabilities | ||||||||||||
| Accounts payable | $3.5M | $807,000 | $4.4M | $451,000 | $3.9M | $6.6M | $8.5M | $7.7M | $8.9M | $2.3M | $8.8M | $5.5M |
| Short-term debt | $1.7M | $2.7M | $3.7M | $4.0M | $3.9M | $3.9M | $3.8M | $3.8M | $3.8M | $3.7M | $3.6M | $3.6M |
| Deferred revenue | $9.0M | $9.3M | $21.6M | $19.1M | $13.5M | $14.0M | $21.0M | $19.7M | $26.7M | $26.1M | $28.4M | $2.0M |
| Total current liabilities | $31.5M | $21.9M | $41.8M | $31.7M | $135.1M | $84.9M | $98.0M | $91.3M | $84.2M | $75.0M | $80.7M | $48.7M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $1.7M | $2.7M | $3.7M | $50.0M | $5.1M | $6.0M | $6.8M | $7.6M | $8.4M | $9.1M | $9.9M | $10.6M |
| Other long-term liabilities | $34.4M | $36.4M | $29.3M | $33.0M | $41.2M | $45.5M | $40.9M | $46.1M | $42.2M | $45.6M | $47.1M | $7.0M |
| Total liabilities | $65.9M | $58.3M | $71.1M | $64.7M | $176.3M | $130.4M | $138.9M | $137.4M | $126.4M | $120.6M | $127.8M | $55.7M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $16,000 | $16,000 | $17,000 | $17,000 | $12,000 | $12,000 | $12,000 | $12,000 | $11,000 | $10,000 | $8,000 | $7,000 |
| Retained earnings (deficit) | −$8.1M | $12.1M | −$1.58B | −$1.34B | −$1.17B | −$1.01B | −$893.1M | −$790.8M | −$710.4M | −$639.6M | −$570.8M | −$510.3M |
| Accumulated other comprehensive income | −$235,000 | — | $2.6M | $1.8M | $1.8M | $2.8M | $2.9M | $7.1M | −$453,000 | −$464,000 | $125,000 | −$1.9M |
| Total shareholders' equity | $214.6M | $234.1M | $207.3M | $212.9M | $1.19B | $1.33B | $1.42B | $1.50B | $1.22B | $830.9M | $500.8M | $517.5M |
| Key figures | ||||||||||||
| Total debt | $1.7M | $2.7M | $3.7M | $4.3M | $5.1M | $6.0M | $6.8M | $7.6M | $8.4M | $9.1M | $9.9M | $10.6M |
| Net cash (debt) | $262.5M | $265.2M | $266.3M | $265.7M | $1.18B | $1.37B | $1.49B | $1.58B | $1.29B | $906.7M | $585.5M | $532.0M |
| Working capital | $243.5M | $263.7M | $231.0M | $239.5M | $1.12B | $1.35B | $1.44B | $1.53B | $1.24B | $859.5M | $530.6M | $506.8M |
| Tangible book value | $214.6M | $234.1M | $207.3M | $212.9M | $1.19B | $1.33B | $1.42B | $1.50B | $1.22B | $830.9M | $500.8M | $517.5M |
| Book value per share | $12.54 | $13.69 | $12.11 | — | — | — | — | — | — | — | $6.58 | $6.98 |
| Shares outstanding | 17.1M | 17.1M | 17.1M | — | — | — | — | — | — | — | 76.1M | 74.1M |
| Current ratio | 8.73 | 13.04 | 6.53 | 8.55 | 9.26 | 16.91 | 15.73 | 17.76 | 15.78 | 12.47 | 7.58 | 11.40 |
| Quick ratio | 8.39 | 12.91 | 6.76 | 8.98 | 8.82 | 16.69 | 15.61 | 17.60 | 15.61 | 12.34 | 7.49 | 11.16 |
| Debt / equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
| Equity / assets | 76.5% | 80.1% | 74.5% | 76.7% | 87.1% | 91.1% | 91.1% | 91.6% | 90.6% | 87.3% | 79.7% | 90.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
RNA financial position
At the end of fiscal 2025 (December 31, 2025), Atrium Therapeutics had total assets of $278.4 million (down 82.2% from a year earlier), total liabilities of $71.1 million and shareholders' equity of $207.3 million. It held $270.0 million in cash and short-term investments against $3.7 million of debt, a net cash position of $266.3 million. Its current ratio was 6.53. In the latest quarter (ended June 30, 2026) total assets were $280.5 million and equity $214.6 million.
Related: RNA income statement, RNA cash flow statement, RNA key metrics. See the RNA stock overview for the latest quote and news.
RNA balance sheet FAQ
What are Atrium Therapeutics's total assets?
Atrium Therapeutics reported total assets of $278.4 million at the end of fiscal 2025 (December 31, 2025), compared with $1.6 billion a year earlier.
How much debt does Atrium Therapeutics have?
Atrium Therapeutics had $3.7 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.02.
How much cash does Atrium Therapeutics have?
Atrium Therapeutics held $270.0 million in cash and short-term investments at the end of fiscal 2025; with $3.7 million of debt that is net cash of $266.3 million.
What is Atrium Therapeutics's book value?
Atrium Therapeutics's shareholders' equity (book value) was $207.3 million at the end of fiscal 2025, or $12.11 per share.
What is Atrium Therapeutics's current ratio?
Atrium Therapeutics had current assets of $272.8 million and current liabilities of $41.8 million, a current ratio of 6.53 (it can cover its short-term obligations).